Soluble CD23 Expression in Asthma Patients Treated With OMA

Part of paid clinical trials in Jackson, Mississippi.

Sponsor
University of Mississippi Medical Center
Study ID
NCT00226200
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab will have the same effect on non-allergic asthmatics as it does allergic asthmatics.

Key Dates

Start date
Nov 30, 2004
Status verified
Nov 2008
Primary completion
Oct 31, 2007
Completion
Oct 31, 2007

Study Design

Enrollment
80 participants
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Measure of sCD23 in plasma

Locations (1)

FacilityCityStateZIPSite coordinators
University of Mississippi Medical CenterJacksonMississippi39216-

Find similar trials in Jackson, MS

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
University of Mississippi Medical Center· Jackson, MS

Related Studies